has 174,477 shares left for registered sales.
Nektar Therapeutics is estimated to report earnings on 2/28/2019
Think he knows something?
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows: - revenues from licensing and collaboration agreements (68.6%); - royalties (20.8%); - product sales…
https://www.finviz.com/insidertrading.ashx?tc=2